论文部分内容阅读
局部晚期非小细胞肺癌(NSCLC)的治疗是多学科关注的热点。局部晚期非小细胞肺癌是具有明显异质性的肿瘤,包括不可手术和经过多学科讨论适合手术的Ⅱ~Ⅲ期患者。多数指南根据第7版TNM分期把局部晚期NSCLC定义为Ⅲ期NSCLC患者~([1-4])。参考第7版TNM临床分期系统,约34.0%的TNM分期Ⅲ期~([3]),第8版TNM临床分期系统,约36.0%的TNM分期Ⅲ期~([3])。因为治愈率和远期预后的不同,又分为
Treatment of locally advanced non-small cell lung cancer (NSCLC) is a multidisciplinary focus. Local advanced non-small cell lung cancer is a significantly heterogeneous tumor, including inoperable and multidisciplinary discussion of appropriate surgery in patients with stage Ⅱ ~ Ⅲ. Most guidelines define locally advanced NSCLC as stage III NSCLC according to the seventh edition of the TNM staging ~ (1-4). With reference to the 7th edition of the TNM clinical staging system, about 34.0% of the TNM staging phase III to the 8th TNM clinical staging system and about 36.0% of the TNM staging phase III to 3 are eligible. Because the cure rate and long-term prognosis is different, is divided into